Strong Revenue Growth
Niagen Biosciences reported $30.5 million in revenue for Q1 2025, marking a 38% year-over-year increase.
Net Income Achievement
The company achieved a net income of $5.1 million, a significant improvement from a net loss of $0.5 million in the previous year.
E-commerce and Ingredient Growth
E-commerce sales grew by 31% year-over-year, while the Niagen ingredient business saw a 95% increase.
Expansion of Niagen Plus
Niagen Plus is now available in nearly 600 clinics nationwide, with plans to expand to 1,000 by year-end.
Patent Portfolio Expansion
A new composition of matter patent was granted, expanding protection for all salt forms of nicotinamide riboside.
Improved Gross Margin
Gross margin improved to 63.4%, up from 60.7% the previous year.
Increased Cash Flow
Net cash provided by operations was $7.9 million, compared to $300,000 in the same period last year.
Raised Full-Year Revenue Outlook
The full-year top-line growth outlook was raised to 20% to 25% year-over-year.